Severe asthma ILC2s demonstrate enhanced proliferation that is modified by biologics.

Bilal MalikNathan W BartlettJohn W UphamKristy S NicholJohn Harrington Peter A B Wark

Published in: Respirology (Carlton, Vic.) (2023)

ILC2s from severe allergic and eosinophilic asthma demonstrated an active phenotype typified by increased proliferation, TSLPR, GATA3 and NFATc1 expression and increased IL-5, IL-13 and IL-6 release. Mepolizumab reduced markers of ILC2s activation.

Keyphrases

signaling pathway
poor prognosis
nk cells
transcription factor
chronic obstructive pulmonary disease
cystic fibrosis
long non coding rna
drug induced
air pollution